about
Huge parathyroid carcinoma: clinical considerations and literature reviewElectrochemotherapy in pancreatic adenocarcinoma treatment: pre-clinical and clinical studiesInduction of VX2 para-renal carcinoma in rabbits: generation of animal model for loco-regional treatments of solid tumors.(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial.Hepatocellular carcinoma and liver metastases: clinical data on a new dual-lumen catheter kit for surgical sealant infusion to prevent perihepatic bleeding and dissemination of cancer cells following biopsy and loco-regional treatments.Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma.Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short Radiotherapy--rectum 3rd trial).Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas.A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme).Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): a case report.Sequential PET/CT with [18F]-FDG Predicts Pathological Tumor Response to Preoperative Short Course Radiotherapy with Delayed Surgery in Patients with Locally Advanced Rectal Cancer Using Logistic Regression AnalysisJuvenile Huntington's disease: does a dosage-effect pathogenic mechanism differ from the classical adult disease?Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma.Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial.Standardized Index of Shape (DCE-MRI) and Standardized Uptake Value (PET/CT): Two quantitative approaches to discriminate chemo-radiotherapy locally advanced rectal cancer responders under a functional profile.Surgical management of sentinel lymph node biopsy outside major nodal basin in patients with cutaneous melanoma.Targeted therapy: a new hope for thyroid carcinomas.Evaluation of a CdTe semiconductor based compact γ camera for sentinel lymph node imaging.Prediction of efficacy of octreotide therapy in patients with acromegaly.Electrochemotherapy in locally advanced pancreatic cancer: Preliminary results.Early radiological assessment of locally advanced pancreatic cancer treated with electrochemotherapy.Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.18F-FDG positron autoradiography with a particle counting silicon pixel detector.Somatostatin analogs and prednisone in advanced refractory thymic tumors.(99m)Technetium pentavalent dimercaptosuccinic acid scintigraphy in the follow-up of clinically nonfunctioning pituitary adenomas after radiotherapy.Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab.Age as predictor in patients with cutaneous melanoma submitted to sentinel lymph node biopsy.Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer.Structure-Activity Relationships and Biological Characterization of a Novel, Potent, and Serum Stable C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonist.Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.Radioembolisation in patients with hepatocellular carcinoma that have previously received liver-directed therapies.Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.Role of (68)Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1).Early FDG PET response assessment of preoperative radiochemotherapy in locally advanced rectal cancer: correlation with long-term outcome.Direct evidence of in vitro phosphorylation-dephosphorylation of the estradiol-17β receptor. role of Ca2+-Calmodulin in the activation of hormone binding sitesEvidence that invivo estradiol receptor translocated into nuclei is dephosphorylated and released into cytoplasmPhosphorylation of calf uterus 17β-estradiol receptor by endogenous Ca2+-stimulated kinase activating the hormone binding of the receptorATP-dependent enzyme activating hormone binding of estradiol receptorSentinel Node Biopsy in Thin and Thick Melanoma
P50
Q24814295-94C784C4-6A89-4706-9F93-661721333D80Q26749111-A404D8E9-E371-400B-96D2-9ED7BC654747Q30367899-B969DD7A-256C-4C5B-BDB9-FD122EA674A5Q30581273-1EA908BD-0155-47A1-804A-4065C7C97164Q30937758-79D2BF9F-96D4-484A-AA00-B61DA18011F0Q33412734-3F20BFE2-D7D7-494F-95F3-CBDE8213B525Q34898391-A8311730-A553-4B06-AEF4-61524FE0138EQ35686954-2A2BE642-DDAE-4001-B75B-E7A66FDB4687Q35917810-B1EF22C9-6145-40BF-BA7B-1027422FF3BDQ36175784-14A7C98B-7E30-4D8E-BB5F-5B944608B1D6Q36242706-7E128152-B849-4D02-B1E0-C172450E3B70Q36308082-06F72396-496A-40A4-814E-D4E172BF0471Q36687470-C726F435-2E9F-4100-B751-417DC0193047Q36889705-A210C4CF-F942-45C8-A5BD-22C685381C51Q37702677-4FEE2C6D-396C-445D-A43A-FA3C7CE1EFB4Q38148060-25329A7E-8DD2-48F7-8AB4-B86264C4E8CAQ38281399-F4DD19E8-0029-4F25-B45B-F0BA22FBA3E4Q39757047-7B3EA062-0EF7-4D2C-BB28-BA5F170F5DB0Q40936987-2786308D-FCE8-4855-8116-372574027DF4Q41008276-9B81626E-D98E-4B36-9F38-135B02E90340Q41042295-C9401AB1-5FE4-41F6-A211-BB194496877BQ42486526-276B76F0-1227-4AD1-83B6-6230F648042EQ43586008-9A85D4CA-447F-463D-A63E-0ADDB576630FQ43804746-BA5DCEDD-A2A2-45E0-BA18-765DA106DF5CQ43937936-BA84C407-ACAB-4123-89EC-C8C4C065C0D5Q44033167-4BCD411B-225C-405F-B308-44147DDD61B4Q44248609-BA84463C-8E60-4274-B58C-4C13849A7959Q45251843-D267A748-7900-45F8-886A-9648C1BA916BQ46121546-C6E2F627-C1E6-4D87-A12C-66FA0B1F33C1Q47417227-399D8FE2-B312-401F-8A2D-8A5E61407279Q50535030-822A0E93-2DE0-4597-BFC1-7D5007F8E42DQ51743178-267D0240-9124-497E-AF55-306A54B344E0Q51873576-548C1B28-A879-45C0-818E-32D8ED4EDF22Q52992707-69177A4D-27D7-4E3F-801F-EB009EBC6E6EQ53137607-7DBF7E29-B4E0-4AC1-950E-C19A4EBF91BFQ58159181-877B15BF-0FBB-478C-85A1-5DBEE536ADFDQ58159194-3D010826-25ED-4670-AE86-C16386A0E2E0Q58159201-A8CA5437-80E2-4B70-AD40-5091ABB4A588Q58159208-B132763E-803A-42BE-B5D0-A2E5E2CC0CD3Q59489494-42886185-14A0-4B74-BE8D-41895C825B2F
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Secondo Lastoria
@ast
Secondo Lastoria
@en
Secondo Lastoria
@es
Secondo Lastoria
@nl
type
label
Secondo Lastoria
@ast
Secondo Lastoria
@en
Secondo Lastoria
@es
Secondo Lastoria
@nl
prefLabel
Secondo Lastoria
@ast
Secondo Lastoria
@en
Secondo Lastoria
@es
Secondo Lastoria
@nl
P108
P106
P1153
57192325605
P31
P496
0000-0002-6649-9903